Newsletter Tool

Featured Story

Menarini, chased by 3 Big Pharmas, records win in breast cancer phase 3, plots path to FDA

By Nick Paul Taylor

Menarini and Radius Health have gained a lead over AstraZeneca, Roche and Sanofi in the race to bring a new class of oral breast cancer drugs to market, posting phase 3 data and outlining plans to seek approvals on both sides of the Atlantic next year.

Amazon expanding virtual care service to 5 additional cities this year

By Heather Landi

Amazon continues to eye the employer market with its Amazon Care service and plans to expand to five major cities this year, an executive at the online retail giant said this week.

FDA approves Luminopia's VR-based digital therapeutic which treats lazy eye with TV time

By Andrea Park

In a dream come true for kids, rather than dissuading their pediatric patients from watching too much TV, physicians may now actually prescribe screen time as part of a therapeutic regimen.

Johnson & Johnson preps for first CAR-T launch with a new patient support program, a dedicated sales team and more

By Angus Liu

Johnson & Johnson and partner Legend Biotech are expecting an FDA decision for their first CAR-T product, cilta-cel, in November. To prepare for the upcoming launch of the personalized cell therapy, the Big Pharma company is planning a specialized patient support program.

Ventyx nabs a $152M upsized IPO to challenge BMS' Zeposia—and a backer with intimate knowledge of its rival

By Ben Adams

Ventyx Biosciences is in the fast lane: Less than a year ago, the biotech emerged from stealth with big plans to dampen down some blockbuster autoimmune/inflammation targets. Then last month, it sprinted to Wall Street with the now standard $100 million IPO ticket.

Pfizer, Merck next-gen pneumococcal vaccines score key CDC panel's backing on way to rival rollouts

By Eric Sagonowsky

With a new vote from CDC vaccine advisors, the U.S. appears set for rival pneumococcal vaccine rollouts from two of the industry's biggest players. A clash between Merck and Pfizer will "have to be decided on the market," one analyst wrote.

CMMI rolls out strategic refresh to make payment models more equitable and streamlined

By Robert King

CMMI unveiled a strategic refresh that will guide the development of value-based care models over the next decade, with overarching goals of ensuring models address health disparities.

More activist pressure for Merck's $11.5B Acceleron deal as another hedge fund balks—but BMS appears ready to deal

By Angus Liu

Merck & Co.’s proposed $11.5 billion acquisition of Acceleron Pharma is getting more pushback from yet another vocal opponent. This time, the activist investor is asking for what seems to be the impossible—twice as much as Merck’s offer.

Another $80M: mRNA biotech ReCode matches 2020 series A with Pfizer, Sanofi money for cystic fibrosis trial

By Kyle LaHucik

ReCode Therapeutics is back with its second $80 million financing round, this time a series B from Pfizer, Sanofi and VC shops, to bring its lead programs into human trials. Up first are cystic fibrosis and primary ciliary dyskinesia, another lung disease.

Zerigo Health beams up $43M from Bayer, Cigna and more for at-home psoriasis UV light therapy

By Andrea Park

As COVID-19 shut down non-emergency procedures, the demand for at-home treatments reached new heights and sent investors scrambling to throw their weight behind new software, devices and programs to reach patients in their own homes. Investors’ latest target is Zerigo Health, maker of an FDA-cleared system for self-administering ultraviolet light therapy to treat psoriasis, vitiligo and eczema.

HLTH21: Traditional healthcare is missing younger consumers. How can providers win them back?

By Dave Muoio

Convenient, accessible and transparent care services are in high demand among younger generations with little patience for a poor patient experience, executives from consumer and millennial-serving health brands said in Boston.

PM Tracker